Dr. Ronald Shore is an acclaimed dermatologist practicing in Montgomery County, Maryland. He was born and raised in Canada, where he attended and graduated from the University of Saskatchewan School of Medicine as a Doctor of Medicine with Great Distinction. He received multiple accolades during his academic career, including 11 academic scholarships. Following medical school, Dr. Shore completed an internship and fellowship in medicine at Johns Hopkins Hospital and a residency in dermatology at the University of Pennsylvania. Upon graduating, he relocated to Maryland in 1977 and has been in private practice in the field of dermatology ever since.

Throughout his long and illustrious career, he has enjoyed a multitude of medical accomplishments, including contributing to the teaching program for dermatology residents and medical students at Johns Hopkins for over 30 years, authoring over 40 medical papers, creating or co-creating several diagnostic tests, lecturing internationally, and hosting courses at Annual Meetings of the American Academy of Dermatology. In addition, Dr. Shore was approached by Johnson and Johnson to develop a new treatment for psoriasis based on his previous research. With a long-time interest and passion for promoting skin cancer screenings, Dr. Shore’s serial screening program for melanoma, which has been in existence for over a quarter of century, has received worldwide attention and is believed to be the longest running cancer screening program to achieve 100% survival of program participants.

In 2012, Dr. Shore contributed to the development of the “Paula’s Test”, a revolutionary new blood test that screens for lung cancer. The test, which was developed by the biotech company 20/20 GeneSystems, was named after Dr. Shore’s wife, who died from lung cancer.

In 2013 Dr. Shore co-founded the Delivering Cures for Cancer Foundation to honor his late wife.

Dr. Joseph Fox is a renowned surgeon and board-certified podiatrist maintaining a private practice in New York. Dr. Fox attended medical school at New York College of Podiatric Medicine, completed postgraduate work at Johns Hopkins School of Public Health and Hygiene, and completed his residency through the Maryland Hospital Network Podiatry Residence Program. Dr. Fox has had over 35 years of experience in both his medical practice and teaching the surgical residents in several major New York City Hospitals. He is currently on staff at Weil-Cornell New York-Presbyterian Hospital as a clinical attending in the Department of Surgery. In addition, he was acknowledged by New York City Mayor Giuilani as a first responder on 9/11 and serves as the podiatry consultant to organizations such as the United Nations and several ballet and theatre companies – honors shared only by a small elite group of medical professionals around the world. He has also been recognized on an international level for his work in establishing worldwide clinics that specialize in wound care and diabetic foot care.

In addition to his pioneering work in the field of podiatry, Dr. Fox has devoted a great deal of his time and energy to cancer-focused efforts. He also has contributed to and affiliated himself with the Angiogenesis Foundation.

Dr. Esther Chang is a member of the Departments of Oncology and Otolaryngology at the Lombardi Comprehensive Cancer Center of Georgetown University Medical Center. Before joining Georgetown University, Dr. Chang held positions in the National Cancer Institute as a Cancer Expert, as a professor in the Department of Surgery at Stanford University, and as a professor in the Departments of Pathology and Surgery at the Uniformed Services University of Health Sciences. Currently, she is serving as the President of the American Society for Nanomedicine and is also an Executive Board Member of the International Society for Nanomedicine (ISNM) in Basel.

Dr. Chang is the founding scientist of, as well as a Senior Consultant, for SynerGene Therapeutics, Inc. Dr. Chang’s research effort focuses primarily on the molecular mechanisms of carcinogenesis and in translating this basic information into new clinical modalities. She believes that delineation of the roles of various genetic factors, transforming oncogenes and tumor suppressor genes, in the multistep process of tumor formation, is the key to improved diagnosis and effective therapy of cancer.

Dr. Chang has been a pioneer and a major contributor to understanding genetic influences on both the development and suppression of malignant tumors, as well as to understanding the molecular basis of tumors’ resistance to radiation and chemotherapy. She was the first to identify human versions of a mouse viral oncogene and to demonstrate the role of these “ras oncogenes” in carcinogenesis. As determined by Current Contents, two of Dr. Chang’s seminal papers on this topic are among the top 100 most-cited publications in Life Sciences (1982-84). Her research group also was the first to demonstrate, simultaneously with another, that a mutated p53 gene (which has since been identified as one of the most frequently altered genes in human cancer) is the primary genetic defect in a cancer-prone family with Li-Fraumeni Syndrome. Dr. Chang’s publication on this finding is among the top 10 most-cited publications in Medicine (1991-92), according to Science Watch. One of Dr. Chang’s publications was selected as the recipient of the 2010 Herbert M. Stauffer Award for Best Basic Science paper in early cancer diagnosis.

Dr. Chang’s research on the application of nanotechnology to cancer therapy, diagnosis and prevention was recognized in Science News Magazine as among the most promising efforts in the field. Most recently, her research group has been evaluating the combination of systemic, tumor-targeted gene therapy and more conventional radiotherapy or chemotherapy for treatment of cancers. These nanotechnology-based therapeutic approaches have been shown to systemically deliver the p53 gene, homing specifically, not only to the primary tumor, but also to the metastases, which are the ultimate cause of so many cancer deaths. This nanodelivery system, carrying the human tumor suppressor gene p53, has just completed a Phase Ia clinical trial as a single agent. The agent has been shown to be safe with anti-cancer effect. A Phase Ib combination trial with p53 and Docetaxel is currently ongoing. A Phase Ib/II trial with p53 and gemcitabine in patients with advanced pancreatic cancer has just received FDA approval.

Another human tumor suppressor gene RB94, as a payload delivered by the same nano-system, has demonstrated marked anti-tumor efficacy in pre-clinical studies. A Phase I Safety Trial of the agent is currently ongoing. The nanodelivery system represents a much broader nanotechnology platform in that the payload is not only limited to gene medicine, but also is applicable to siRNAs/miRNAs, antisense oligonucleotides, imaging agents, small molecules, and chemotherapeutic agents.

Dr. Chang has over 130 publications, is the inventor of 100 issued patents, and has served as a member of a number of scientific advisory boards for the National Cancer Institute, NASA, the US Military Cancer Institute, and the Department of Energy. Her scientific findings have been published in prominent journals including Nature, Science, Cancer Research, Cell, Human Gene Therapy, among others. She also has dedicated much time to the education of undergraduate, graduate and medical students. Dr. Chang has held peer reviewed grants from the NIH for more than 29 years without interruption. She is the Principal Advisor to the Delivering Cures for Cancer Foundation, which is dedicated to accelerating the availability of a cure for cancer using cancer-targeted, nanomedicine-based delivery systems.

Professor Michio Kaku is an American theoretical physicist, futurist, and popularizer of science. Kaku is a professor of theoretical physics at the City College of New York and CUNY Graduate Center. He has written several books about physics and related topics, has made frequent appearances on radio, television, and film, and writes online blogs and articles. He has written three New York Times best sellers: Physics of the Impossible (2008), Physics of the Future (2011), and The Future of the Mind (2014). Kaku has hosted several TV specials for the BBC, the Discovery Channel, the History Channel, and the Science Channel.
Kaku has appeared in many forms of media and on many programs and networks, including Good Morning America, The Screen Savers, Larry King Live, 60 Minutes, Imus In The Morning, Nightline, 20/20, Naked Science, CNN, ABC News, CBS News, NBC News, Al Jazeera English, Fox News Channel, The History Channel, Conan, The Science Channel, The Discovery Channel, TLC, Countdown with Keith Olbermann, The Colbert Report, The Art Bell Show and its successor, Coast to Coast AM, BBC World News America, The Covino & Rich Show, Head Rush, Late Show with David Letterman, and Real Time with Bill Maher. Kaku is popular in mainstream media because of his knowledge and his accessible approach to presenting complex subjects in science. While his technical writings are confined to theoretical physics, his public speaking and media appearances cover a broad range of topics, from the Kardashev scale to more esoteric subjects such as wormholes and time travel.

Janine Shore wants to make the best use of her time on this planet. Having watched her mother suffer through cancer treatment, Ms. Shore, a driven entrepreneur and former entertainment industry executive, knew she could do more. Even after receiving an international distribution deal for her award-winning films and completing a contract with Universal Records producing music videos for MTV, she resigned from a promising career with a skyrocketing trajectory. Since 2012, Ms. Shore has been dedicated to advancing the standard of cancer care.

Ms. Shore, who holds a B.S. in Communications from Boston University, spends much of her time in her role as CEO of Delivering Cures for Cancer, a non-profit organization whose mission is to deliver trail-blazing, cutting-edge early detection screening protocols and pioneering treatments for advanced cancer.  In addition to managing a thriving cosmetic dermatology practice, Ms. Shore works tirelessly with governing agencies, biotech companies, and others invested in curing cancer. She has an extensive knowledge of the medical field and cancer treatments, and understands firsthand the challenges associated with treating cancer, the obstacles researchers face in employing new therapies, and the implications for the country’s healthcare system.

Under Ms. Shore’s leadership, Delivering Cures for Cancer is actively working to further fund the pioneering research by world-renowned Nanotechnologist and Oncologist, Dr. Esther Chang, of Georgetown University Lombardi Cancer Center. Dr. Chang is currently President of the American Society for Nanomedicine, and has developed a treatment for advanced stage cancers that utilizes tumor-targeted nanomedicine technology This treatment delivers encapsulated drugs and tumor suppressing genes to cancer cells only, without affecting the body’s healthy cells, tissue, and organs. Dr. Michio Kaku, renowned theoretical physicist, New York Times best-selling author and media consultant coined the term “the Holy Grail of Cancer Research” to describe Dr. Chang’s Nanomedicine Delivery System.

This treatment increases the effectiveness of drugs, corrects damaged genes, passes the blood brain barrier, and eliminates the toxic side effects associated with traditional chemotherapy. In current, on-going Phase II FDA clinical trials, employing this therapy has resulted in apoptosis (programmed cancer cell death), and a reduction in size of primary tumors and metastases. Thus, making inoperable cancers operable and has yielded unparalleled published results.

As CEO of Delivering Cures for Cancer, Ms. Shore is frequently invited to participate in speaking engagements, where she presents this research, and was a keynote speaker at the 2018 NASA Goddard Safety Awareness Week. She advocates a new way of thinking about cancer treatment and promotes combining current therapies with the latest technologies to make treatments more effective, humane, and economical. Ms. Shore is looking to this new research model that brings to light promising therapies to cure cancer, save lives and preserve families.

Get the latest updates on our research.

Delivering Cures for Cancer
4701 Randolph Rd.
Suite 207
Rockville MD 20852
*All donations are tax deductible.


support us and change
the future of cancer.

Drs. Ronald Shore and Joseph Fox, who founded Delivering Cures for Cancer and The Paula Shore/Sari Fox Foundation, receive no salary, income or other compensation from the Foundation. Their donations have covered the majority of the start up costs including website, legal, accounting, administrative, and promotions expenses. Dr. Shore, whose skin cancer screening program is described on this website, has helped to educate fellow dermatologists and other medical personnel on how to perform highly effective skin cancer screening through international lectures and publications, largely at personal expense. Honoraria for his presentations, if provided, have been returned to the institution (e.g. University of Pennsylvania), or given to charity (e.g. The Society for Dermatologic Physician Assistants).  He receives no other compensation from industry, academic institutions or other entities. Dr. Shore has volunteered his time and knowledge on screening to 20/20 GeneSystems, Inc., the developer of the PAULAs Test, a new blood test for early detection of lung cancer.  He has also served on its Medical Advisory Board. He has received no remuneration for these forms of assistance. Dr. Shore and Dr. Fox were each approached by 20/20 GeneSystems, Inc. to purchase shares to help the company continue its research, and both agreed to do so. Their investments in the company, in each case, represent well under 1% of total investments. Neither physician holds any controlling or voting position in the company, nor draws any salary or other compensation. Dr. Shore and Dr. Fox, who for several years have spoken to various individualsorganizations and government personnel to try to advance Dr. Esther Chang’s research, were each approached by SynerGeneTherapeutics, Inc., the financial entity helping to fund her research, to purchase shares to help her continue her clinical trials. Both agreed to do so. Their investments in the company, in each case, represent well under 1% of total investments.  Neither physician holds any controlling or voting position in the company, nor draws any salary or other compensation. Other members of the Shore and Fox families have assisted the development of the Foundation and its website through donations, administrative assistance, and technical assistance preparing the videos.  No members of either family have drawn salaries nor received other compensation. Dr. Esther Chang was asked by the Founders to act as an advisor and to provide technical assistance, particularly regarding development of the videos on the website that explain her technology, and she agreed to do so.  She holds no controlling or voting position on Delivering Cures for Cancer or the Paula Shore/Sari Fox Foundation, nor draws any salary or other compensation. Delivering Cures for Cancer (DC4C) was formerly known as, and remains the organization’s legal 501(c)(3) entity under the name The Paula Shore/Sari Fox Foundation (PSSF). Dr. Ronald Shore, Dr. Joseph Fox – December 31, 2014